pubmed-article:15015625 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C1825590 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C2697648 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
pubmed-article:15015625 | lifeskim:mentions | umls-concept:C1285530 | lld:lifeskim |
pubmed-article:15015625 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:15015625 | pubmed:dateCreated | 2004-3-12 | lld:pubmed |
pubmed-article:15015625 | pubmed:abstractText | The aim of this work was to evaluate the efficacy and safety of second-line treatment with weekly high-dose 5-Fluorouracil (5-FU) as a 24-hour infusion (24-h inf.) and folinic acid (FA) (AIO-regimen) plus Oxaliplatin (L-OHP) after pre-treatment with the AIO regimen, focusing in particular on the efficacy of palliative first- and second-line treatment in colorectal carcinoma (CRC). | lld:pubmed |
pubmed-article:15015625 | pubmed:language | eng | lld:pubmed |
pubmed-article:15015625 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15015625 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15015625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15015625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15015625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15015625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15015625 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15015625 | pubmed:issn | 0250-7005 | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:LinnLL | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:WeilCC | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:MerkelSS | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:HahnE GEG | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:HohenbergerWW | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:GöhlJJ | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:BrücklW MWM | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:HappichKK | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:SchirnerII | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:JüngertBB | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:BrücklVV | lld:pubmed |
pubmed-article:15015625 | pubmed:author | pubmed-author:MännleinGG | lld:pubmed |
pubmed-article:15015625 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15015625 | pubmed:volume | 24 | lld:pubmed |
pubmed-article:15015625 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15015625 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15015625 | pubmed:pagination | 385-91 | lld:pubmed |
pubmed-article:15015625 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:meshHeading | pubmed-meshheading:15015625... | lld:pubmed |
pubmed-article:15015625 | pubmed:articleTitle | Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC). | lld:pubmed |
pubmed-article:15015625 | pubmed:affiliation | Department of Internal Medicine I, University of Erlangen, Germany. | lld:pubmed |
pubmed-article:15015625 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15015625 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:15015625 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:15015625 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |